Sign Up
Stories
BMY Expands Portfolio with RayzeBio Acquisition
Share
4P-Pharma Secures €15 Million Funding
ABBio Innovates Antibody Development
ABIONYX Pharma Files 2023 Document
ADOCIA Files 2023 Registration Document
ANJESO Drug Insight and Market Forecast
Afya Limited Expands Medical Seats in Br...
Overview
API
Bristol Myers Squibb has successfully acquired RayzeBio, incorporating a unique Actinium-based radiopharmaceutical platform and RYZ101 program for solid tumors. The strategic $4.1 billion deal expands BMY's oncology portfolio beyond immunotherapy, fostering growth prospects.
Ask a question
How might the incorporation of RayzeBio's radiopharmaceutical platform impact BMY's market position?
In what ways could the RYZ101 program revolutionize cancer treatment approaches?
What challenges and advantages could arise from diversifying BMY's oncology pipeline?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage